false0001041024 0001041024 2020-08-07
2020-08-07
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to
Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): August
10, 2020
ROCKWELL
MEDICAL, INC.
(Exact name of
registrant as specified in its charter)
|
|
|
|
|
Delaware
|
000-23661
|
38-3317208
|
|
(State or other
jurisdiction
of
incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification
No.)
|
411 Hackensack Avenue,
Suite 501,
Hackensack,
New Jersey
07601
(Address of
principal executive offices, including zip code)
(248)
960-9009
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former name or
former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
|
|
|
|
|
☐
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
|
|
|
|
☐
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)
|
Securities registered
pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of Each Class
|
|
Trading Symbol
|
|
Name of Each exchange on which
registered
|
|
Common Stock, par value
$0.0001
|
|
RMTI
|
|
Nasdaq Global
Market
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02 Results
of Operations and Financial Condition.
On August 10,
2020, Rockwell Medical, Inc. issued a press release and earnings
presentation announcing its financial results for the quarter ended
June 30, 2020. The press release and earnings presentation are
furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this
Current Report on Form 8‑K.
As provided in General
Instruction B.2 of Form 8-K, the information in this Item 2.02 and
Exhibits 99.1 and 99.2 incorporated in this Form 8-K shall not be
deemed to be “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, nor shall such information or Exhibits 99.1
and 99.2 be deemed to be incorporated by reference in any filing
under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such a
filing.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits The
following exhibit is being furnished herewith:
EXHIBIT INDEX
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
|
|
99.2
|
|
|
|
104
|
|
Cover Page Interactive Data
File, formatted in INline XBRL and included as Exhibit
101.
|
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
ROCKWELL
MEDICAL, INC.
|
|
|
|
|
|
Date: August 10,
2020
|
By:
|
/s/ Russell
Ellison
|
|
|
|
Russell Ellison
|
|
|
|
Chief Executive
Officer
|
